Diabetic retinopathy

Minerva Medica

Volumn 94, Issue 6, 2003, Pages 419-435

  Grassi, G ^a,b  

^a MOLINETTE HOSPITAL   (Italy)

^b U O Diabetologia   (Italy)

Author keywords

Diabetes mellitus, complication; Diabetic retinopathy, diagnosis; Diabetic retinopathy, therapy

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALDOSE REDUCTASE INHIBITOR; ANGIOPEPTIN; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BENFOTIAMINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; NISOLDIPINE; OCTREOTIDE; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN KINASE C INHIBITOR; RENIN INHIBITOR; RUBOXISTAURIN; SOMATOSTATIN DERIVATIVE; SORBINIL; STEROID; THIAMINE DERIVATIVE; TOLRESTAT;

ARTERIOLE; BLINDNESS; CAPILLARY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; EUROPE; HUMAN; HYPERTENSION; LASER COAGULATION; LASER SURGERY; MICROANGIOPATHY; NORTH AMERICA; PREVENTIVE MEDICINE; PROLIFERATIVE RETINOPATHY; RANDOMIZATION; RETINA MACULA EDEMA; REVIEW; VENULE; VITRECTOMY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; BLINDNESS; DIABETIC RETINOPATHY; ENZYME INHIBITORS; HUMANS; HYPERGLYCEMIA; HYPERTENSION; LASERS; LIGHT COAGULATION; PREVALENCE; PROTEIN KINASE C; SOMATOSTATIN; VITRECTOMY;

EID: 1942473000     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (155)

1. Watkins PJ. Retinopathy. BMJ 2003;326:924-6.
2. Klein R, Klein BEK, Moss SE. Prevalence of diabetes mellitus in Southern Wisconsin. Am J Epidemiol 1984;119:54-61.
3. Stephenson J, Fuller JH and the EURODIAB IDDM complications study group. Microvascular and acute complications study. Diabetologia 1994;37:278-85.
4. Kernell A, Dedorsson I, Johansson B, Wickstrom CP, Ludvigsson J, Tuvemo T et al. Prevalence of diabetic retinopathy in children and adolescents with IDDM. A population-based multicentre study. Diabetologia 1997;40:307-10.
5. Malone JI, Morrison AD, Pavan PR, Cuthbertson DD. Diabetic control and complications trial. Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years' duration screened for the diabetes control and complications trial. Diabetes Care 2001;24:522-6.
6. Porta M, Sjoelie AK, Chaturvedi N, Stevens L, Rottiers R, Veglio M et al. EURODIAB Prospective Complications Study Group. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 2001;44:2203-9.
7. Palmberg P, Smith M, Waltman S, Krupin T, Singer P, Burgess D et al. The natural history of retinopathy in insulin-dependent juvenile-onset diabetes. Ophthalmology 1981;88:613-8.
8. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-9.
9. Klein R, Klein BE, Moss SE, Linton KL. The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. Ophthalmology 1992;99:58-62.
10. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-32.
11. th ed. Amsterdam: Elsevier; 1996.p.273-300.
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl. J Med 1993;329:977-86.
13. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.
14. [No authors listed]. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 1994;37:278-85.
15. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 1989;149:2427-32.
16. Teuscher A, Schnell H, Wilson PW. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diabetes Care 1988;11:246-51.
17. Araki A, Ito H, Hattori A, Inoue J, Sato T, Shiraki M et al. Risk factors for development of retinopathy in elderly Japanese patients with diabetes mellitus. Diabetes Care 1993;16:1184-6.
18. Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101:1061-70.
19. Moss SE, Klien R, Klien BEK. The incidence of visual loss in a diabetic population. Ophthalmology 1988;95:1340-8.
20. Cruickshanks KJ, Ritter LL, Klein R, Moss SE. The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 1993;100:862-7.
21. Moss SE, Klein R, Klein BE. Ocular factors in the incidence and progression of diabetic retinopathy. Ophthalmology 1994;101:77-83.
22. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-84.
23. Moss SE, Klein R, Klein BE. The association of alcohol consumption with the incidence and progression of diabetic retinopathy. Ophthalmology 1994;101:1962-8.
24. Moss SE, Klein R, Klein BE. Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 1996;103:1438-42.
25. Moss SE, Klein R, Kessler SD, Richie KA. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology 1985;92:62-7.
26. Lim JI, LaBree L, Nichols T, Cardenas I. A comparison of digital nonmydriatic fundus imaging with standard 35-millimeter slides for diabetic retinopathy. Ophthalmology 2000;107:866-70.
27. Kiri A, Dyer DS, Bressler NM, Bressler SB, Schachat AP. Detection of diabetic macular edema: Nidek 3Dx stereophotography compared with fundus biomicroscopy. Am J Ophthalmol 1996;122:654-62.
28. Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Ophthalmology 1991;98(5 Suppl):807-22.
29. Hee MR, Puliafito CA, Duker JS, Reichel E, Coker JG, Wilkins JR et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 1998;105:360-70.
30. Gallemore RP, Jumper JM, McCuen BW 2nd, Jaffe GJ, Postel EA, Toth CA. Diagnosis of vitreoretinal adhesions in macular disease with optical coherence tomography. Retina 2000;20:115-20.
31. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report No 12. Ophthalmology 1992;98:823-33.
32. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 1995;38:437-44.
33. Stellingwerf C, Hardus PL, Hooymans JM. Two-field photography can identify patients with vision-threatening diabetic retinopathy: a screening approach in the primary care setting. Diabetes Care 2001;24:2086-90.
34. Davis MD, Norton EWD, Myers FL. The Airlie House classification of diabetes retinopathy. In: Goldberg MF, Fine SL, editors. Symposium on the treatment of diabetic retinopathy. Washington DC: US Government Printing Office; PHS Pub. No 1890;1969.
35. The Diabetic Retinopathy Study Reserch Group. A modification of the Airlie House classification of diabetic retinopathy. Report No. 7. Invest Ophthalmol Vis Sci 1981;21:210-26.
36. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. Arch Ophthalmol 1995;113:36-51.
37. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M et al. Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular oedema disease severity scales. Ophthalmology 2003;110:1677-82.
38. Four risk factors for several visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy study. Diabetic Retinopathy Study Group DRS. Arch Ophthalmol 1979;97:654-5.
39. Rosenberg T, Klie F. Current trends in newly registered blindness in Denmark. Acta Ophthalmol Scand 1996;74:395-8.
40. Porta M, Tomalino MG, Santoro F, Ghigo LD, Cairo M, Aimone M et al. Diabetic retinopathy as a cause of blindness in the province of Turin, North-West Italy, in 1967-1991. Diabet Med 1995;12:355-61.
41. Ghafour IM, Allan D, Foulds WS. Common causes of blindness and visual handicap in the West of Scotland. Br J Ophthalmol 1983;67:209-13.
42. Munier A, Gunning T, Kenny D, O'Keefe M. Causes of blindness in the adult population of the Republic of Ireland. Br J Ophthalmol 1998;82:630-3.
43. Grey RHB, Malcom N, O'Reilly D, Morris M. Ophtalmic survey of a diabetic clinic. I: Ocular findings. Br J Ophthalmol 1986;70:797-803.
44. Krumpaszky HG, Ludtke R, Mickler A, Klauss V, Selbmann HK. Blindness incidence in Germany. A population-based study from Wurttemberg-Hohenzollern. Ophthalmologica 1999;213:176-82.
45. Vassileva P, Gieser SC, Vitale S, Cholakova T, Katz J, West S. Blindness and visual impairment in Western Bulgaria. Ophthalmic Epidemiol 1996;3:143-9.
46. Doci J, Juhas T, Klisenbauer D, Dora A. [Blindness in Slovakia]. Cesk Oftalmol 1988;44:241-6.
47. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984;91:1-9.
48. Chaturvedi N, Stephenson JM, Fuller JH and the EURODIAB IDDM Complications Study Group. The relationship between socioeconomics status and diabetes control and complications in the EURODIAB IDDM Complications Study. Diabetes Care 1996;19:423-30.
49. Jones RB, Laritzgoitia I, Casado L, Barrie T. How effective is the referral chain for diabetic retinopathy? Diabet Med 1898;6:262-6.
50. Brechner RJ, Cowle CC, Howie L, Herman WH, Will JC, Harris MI. Ophthalmic examination among adults with diagnosed diabetes mellitus. JAMA 1993;270:1714-8.
51. Holland WW, Stewart S. Screening in health care: benefit or bane? London: Nuffield Provincial Hospital Trust; 1990.
52. Kohner EM, Porta M. Screening for diabetic retinopathy in Europe: a field guide-book. Copenhagen: World Health Organization, Regional Office for Europe; 1993.p 1-51.
53. www.diabetic-retinopathy.screening.nhs.uk
54. www.siditalia.it/Pubblicazioni/lineeguida_rd.pdf
55. Younis N, Broadbent DM, Vora JP, Harding SP. Liverpool Diabetic Eye Study. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003;361:195-200.
56. Hutchinson A, McIntosh A, Peters J, O'Keeffe, Khunti K, Baker R et al. Effectiveness of screening and monitoring tests for diabetic retinopathy: a symptomatic review. Diabet Med 2000;17:495-506.
57. Pugh JA, Jacobson JM, Heuven WAJ, Watters JA, Tuley MR, Lairson DR et al. Screening for diabetic retinopaty. The wide-angle retinal camera. Diabetes Care 1993;16:889-95.
58. Massin P, Erginay A, Ben Mehidi A, Vicaut E, Quentel G, Victor Z et al. evaluation of a new non-mydriatic digital camera for detection of diabetic retinopathy. Diabet Med 2003;20:636-41.
59. Gomez-Ulla F, Fernandez MI, Gonzalez F, Rey P, Rodriguez M, Rodriguez-Cid MJ et al. Digital retinal images and teleophthalmology for detecting and grading diabetic retinopathy. Diabetes Care 2002;25:1384-91.
60. Bursell SE, Cavallerano JD, Cavallerano AA, Clermont AC, Birkmire-Peters D, Aiello L et al. Joslin Vision Network Research Team. Stereo nonmydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy. Ophthalmology 2001;108:572-85.
61. Agardh E, Agardh CD, Hansson-Lundblad C. The five-year incidence of blindness after introducing a screening programme for early detection of treatable diabetic retinopathy. Diabet Med 1993;10:555-9.
62. The Diabets Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabets four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9.
63. Hansson-Lundblad C, Holm K, Agardh CD, Agardh E. A small number of older type 2 diabetic patients end up visually impaired despite regular photographic screening and laser treatment for diabetic retinopathy. Acta Ophthalmol Scand 2002;80:310-5.
64. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998-1003.
65. Stefansson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E. Screening and prevention of diabetic blindness. Acta Ophthalmol Scand 2000;78:374-85.
66. Ohkubo Y, Lishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabets mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
67. Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care 1988;11:567-73.
68. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-98.
69. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
70. UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999;22:1125-36.
71. Suzuma I, Hata Y, Clermont A, Pokras F, Rook SL, Suzuma K et al. Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes 2001;50:444-54.
72. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
73. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23 Suppl 2:B54-64.
74. Wilkinson-Berka JL, Kelly DJ, Gilbert RE. The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascolarization in diabetes. J Vasc Res 2001;38:527-35.
75. Wagner J, Jan Danser AH, Derkx FH, de Jong TV, Paul M, Mullins JJ et al. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. Br J Ophthalmol 1996;80:159-63.
76. Davies L, Fulcher GR, Atkins A, Frumar K, Monaghan J, Stokes G et al. The relationship of prorenin values to microvascular complications in patients with insulin-dependent diabetes mellitus. J Diabetes Complications 1999;13:45-51.
77. Sjolie AK, Chaturvedi N. The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy. J Hum Hypertens. 2002;16 Suppl 3:S42-6.
78. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000;36:1099-104.
79. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellari A et al. Effect of lisinopril on progression of retinopathy in normotenoive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998;351:28-31.
80. Chase HP, Garg SK, Harris S, Hoops S, Jackson WE, Holmes DL. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 1993;25:284-9.
81. HOPE. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9. Erratum in: Lancet 2000;356:860.
82. HOPE. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9. Erratum in: Lancet 2000;356:860.
83. UK prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998;317:713-20.
84. The DIRECT programme study group. The Diabetic Retinopathy Candesartan Trials (DIRECT) programme, rationale and study design. J Renin Angiotensin Aldosterone Syst 2002;3:255-61.
85. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002;16:438-40.
86. The TIMAD Study Group. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990;108:1577-83.
87. The DAMAD Study Group. Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 1989;38:491-8.
88. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(5 Suppl):757-65.
89. Gabbay KH. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Annu Rev Med 1975;26:521-36.
90. Sato S, Secchi EF, Lizak MJ, Fukase S, Ohta N, Murata M et al. Polyol formation and NADPH-dependent reductases in dog retinal capillary pericytes and endothelial cells. Invest Ophthalmol Vis Sci 1999;40:697-704.
91. Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990;108:1234-44.
92. van Gerven JM, Boot JP, Lemkes HH, van Best JA. Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. Doc Ophthalmol 1994;87:355-65.
93. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994;43:1122-9.
94. Nagpala PG, Malik AB, Vuong PT, Lum H. Protein kinase C beta 1 overexpression augments phorbol ester-induced increase in endothelial permeability. J Cell Physiol 1996;166:249-55.
95. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98:2018-26.
96. rd, Neel DA et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h] [1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem 1996;39:2664-71.
97. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728-31.
98. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998;39:171-9.
99. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1999;46:1473-80.
100. rd scientific session. 2003; abstract online p. 544.
101. Aiello LP, Davis MD, Milton RC, Sheetz MJ, Arorta V, Vignati L. Initial results of Protein Kinase C β inhibitors Diabetic Macular Edema Study (PKC-DMES). Diabetologia 2003:46 Suppl 2:A42P.
102. Poulsen JE. Recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 1953;2:7-12.
103. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001;33:300-3.
104. Sharp PS, Fallon TJ, Brazier OJ, Sandler L, Joplin GF, Kohner EM. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 1987;30:199-207.
105. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 2000;23:504-9.
106. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996;114:1079-84.
107. Gordon B, Chang S, Kavanagh M, Berrocal M, Yannuzzi L, Robertson C et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 1991;112:385-91.
108. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002;56:1-11.
109. Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy. Eye 2002;16:689-93.
110. Friedman EA. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care 1999;22 Suppl 2:B65-71.
111. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 1984;101:527-37.
112. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46.
113. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 1991;88:11555-8.
114. Spranger J, Osterhoff M, Reimann M, Mohlig M, Ristow M, Francis MK et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001;50:2641-5.
115. Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002;43:821-9.
116. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q et al. Benfotiamine blocks 3 major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003;9:294-9.
117. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-67.
118. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-90.
119. Brignardello E, Beltramo E, Molinatti PA, Aragno M, Gatto V, Tamagno E et al. Dehydroepiandrosterone protects bovine retinal capillary pericytes against glucose toxicity. J Endocrinol 1998;158:21-6.
120. Bursell SE, Clermont AC, Aiello LP, Aiello LM, Schlossman DK, Feener EP et al. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999;22:1245-51.
121. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-7.
122. Proliferative diabetic retinopathy: treatment with xenon-arc photocoagulation. Interim report of multicentre randomised controlled trial. Br Med J 1977;1:739-41.
123. Hercules BL, Gayed II, Lucas SB, Jeacock J. Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three-year interim report of a randomised, controlled study using the argon laser. Br J Ophthalmol 1977;61:555-63.
124. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Groups Ophthalmology 1981;88:583-600.
125. rd. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1992;99:1351-7.
126. Photocoagulation for diabetic maculopathy. A randomized controlled clinical trial using the xenon arc. British Multicentre Study Group. Diabetes 1983;32:1010-6.
127. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(5 Suppl):766-85.
128. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978;85:82-106.
129. Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc 1996;94:505-37.
130. Pearson AR, Tanner V, Keightley SJ, Casswell AG. What effect does laser photocoagulation have on driving visual fields in diabetics? Eye 1998;12(Pt 1):64-8.
131. Henricsson M, Heijl A. The effect of panretinal laser photocoagulation on visual acuity, visual fields and on subjective visual impairment in preproliferative and early proliferative diabetic retinopathy. Acta Ophthalmol (Copenh) 1994;72:570-5.
132. Hamilton AM, Townsend C, Khoury D, Gould E, Blach RK. Xenon arc and argon laser photocoagulation in the treatment of diabetic disc neovascularization. Part 1. Effect on disc vessels, visual fields, and visual acuity. Trans Ophthalmol Soc UK 1981;101:87-92.
133. Blankenship GW. A clinical comparison of central and peripheral argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 1988;95:170-7.
134. Khosla PK, Rao V, Tewari HK, Kumar A. Contrast sensitivity in diabetic retinopathy after panretinal photocoagulation. Ophthalmic Surg 1994;25:516-20.
135. Birch J, Hamilton AM. Xenon arc and argon laser photocoagulation in the treatment of diabetic disc neovascularization. Part 2. Effect on colour vision. Trans Ophthalmol Soc U K 1981;101:93-9.
136. Lovestam-Adrian M, Svendenius N, Agardh E. Contrast sensitivity and visual recovery time in diabetic patients treated with panretinal photocoagulation. Acta Ophthalmol Scand 2000;78:672-6.
137. McDonald HR, Schatz H. Macular oedema following panretinal photocoagulation. Retina 1985;5:5-10.
138. Blankenship GW. Diabetic macular oedema and argon laser photocoagulation: a prospective randomized study. Ophthalmology 1979;86:69-78.
139. Photocoagulation for diabetic macular oedema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985;103:1796-806.
140. Olk RJ. Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular oedema. Ophthalmology 1986;93:938-50.
141. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular oedema. Long-term visual results. Ophthalmology 1991;98:1594-602.
142. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular oedema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987;94:761-74.
143. Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1995;113:1144-55.
144. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Arch Ophthalmol 1985;103:1644-52.
145. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 1990;108:958-64.
146. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial - Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology 1988;95:1307-20.
147. Rice TA, Michels RG, Rice EF. Vitrectomy for diabetic rhegmatogenous retinal detachment. Am J Ophthalmol 1983;95:34-44.
148. Rice TA, Michels RG, Rice EF. Vitrectomy for diabetic traction retinal detachment involving the macula. Am J Ophthalmol 1983;95:22-33.
149. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction-rhegmatogenous retinal detachment. Arch Ophthalmol 1987;105:503-7.
150. Takagi H, Otani A, Kiryu J, Ogura Y. New surgical approach for removing massive foveal hard exudates in diabetic macular oedema. Ophthalmology 1999;106:249-56.
151. Nasrallah FP, Jalkh AE, van Coppenolle F, Kado M, Trempe CL, McMeel JW et al. The role of the vitreous in diabetic macular oedema. Ophthalmology 1988;95:1335-9.
152. Massin P, Duguid G, Erginay A, Haouchine B, Gaudric A. Optical coherence tomography for evaluating diabetic macular oedema before and after vitrectomy. Am J Ophthalmol 2003;135:169-77.
153. Harbour JW, Smiddy WE, Flynn HW, Rubsamen PE. Vitrectomy for diabetic macular oedema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 1996;121:405-13.
154. Tachi N, Ogino N. Vitrectomy for diffuse macular oedema in cases of diabetic retinopathy. Am J Ophthalmol 1996;122:258-60.
155. Otani T, Kishi S. A controlled study of vitrectomy for diabetic macular oedema. Am J Ophthalmol 2002;134:214-9.